Identification

Name
Bosutinib
Accession Number
DB06616
Type
Small Molecule
Groups
Approved
Description

Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.

Structure
Thumb
Synonyms
  • 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile
  • Bosulif®
  • Bosutinib
  • Bosutinib Monohydrate
  • SKI 606
External IDs
SK-606 / SKI-606
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BosulifTablet, film coated100 mg/1OralU.S. Pharmaceuticals2012-09-04Not applicableUs
BosulifTablet, film coated100 mgOralPfizer2013-03-27Not applicableEu
BosulifTablet, film coated100 mgOralPfizer2013-03-27Not applicableEu
BosulifTablet, film coated500 mg/1OralPfizer Laboratories Div Pfizer Inc.2012-09-04Not applicableUs
BosulifTablet500 mgOralPfizer2014-03-24Not applicableCanada
BosulifTablet, film coated500 mgOralPfizer2013-03-27Not applicableEu
BosulifTablet, film coated100 mgOralPfizer2013-03-27Not applicableEu
BosulifTablet100 mgOralPfizer2014-04-24Not applicableCanada
BosulifTablet, film coated100 mg/1OralPfizer Laboratories Div Pfizer Inc.2012-09-04Not applicableUs
BosulifTablet, film coated500 mgOralPfizer2013-03-27Not applicableEu
Categories
UNII
5018V4AEZ0
CAS number
380843-75-4
Weight
Average: 530.446
Monoisotopic: 529.164745233
Chemical Formula
C26H29Cl2N5O3
InChI Key
UBPYILGKFZZVDX-UHFFFAOYSA-N
InChI
InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
IUPAC Name
4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
SMILES
COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl

Pharmacology

Indication

Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Bosutinib is a tyrosine kinase inhibitor. Although it is able to inhibit several tyrosine kinases such as Src, Lyn, and Hck, which are members of the Src-family of kinases, its primary target is the Bcr-Abl kinase. The Bcr-Abl gene is a chimeric oncogene created from the fusion of the breakpoint-cluster (Bcr) gene and Abelson (Abl) tyrosine gene. This chromosomal abnormality results in the formation of what is commonly known as the Philadelphia chromosome or Philadelphia translocation. The Bcr-Abl gene expresses a particular kinase that promotes the progression of CML. A decrease in the growth and size of the CML tumour has been observed following administration of bosutinib. Bosutinib did not inhibit the T315I and V299L mutant cells.

TargetActionsOrganism
ABreakpoint cluster region protein
inhibitor
Human
ATyrosine-protein kinase ABL1
inhibitor
Human
UTyrosine-protein kinase LynNot AvailableHuman
UTyrosine-protein kinase HCK
inhibitor
Human
UProto-oncogene tyrosine-protein kinase Src
inhibitor
Human
UCyclin-dependent kinase 2
inhibitor
Human
UDual specificity mitogen-activated protein kinase kinase 1
inhibitor
Human
UDual specificity mitogen-activated protein kinase kinase 2
inhibitor
Human
UMitogen-activated protein kinase kinase kinase 2
inhibitor
Human
UCalcium/calmodulin-dependent protein kinase type II subunit gamma
inhibitor
Human
Absorption

Food increase the exposure of bosutinib. Tmax, single dose, cancer patients, fed-state = 4-6 hours; After 15 daily doses of bosutinib 500 mg with food in CML patients, the pharmacokinetic parameters are as follows: Cmax = 200 ng/mL; AUC = 3650 ng∙h/mL

Volume of distribution

Apparent volume of distribution = 6080 ± 1230 L.

Protein binding

94% bound to human plasma proteins in vitro. 96% bound to human plasma proteins in healthy subjects ex vivo. Extent of protein binding is not concentration-dependent.

Metabolism

Bosutinib is primarily metabolized by CYP3A4. The major circulating metabolites identified in plasma are oxydechlorinated (M2) bosutinib (19% of parent exposure) and N-desmethylated (M5) bosutinib (25% of parent exposure), with bosutinib N-oxide (M6) as a minor circulating metabolite. All the metabolites were deemed inactive.

Route of elimination

When given a single oral dose, 91.3% of the dose was recovered in feces and 3% of the dose recovered in urine.

Half life

Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours

Clearance

Mean clearance (CL/F), single oral dose, fed-state = 189 L/h

Toxicity

Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue. Because bosutinib is not an inhibitor of c-KIT or PDGF receptor, it has less hematologic toxicities.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Bosutinib Inhibition of BCR-ABLDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbemaciclibThe serum concentration of Bosutinib can be increased when it is combined with Abemaciclib.Approved, Investigational
AcetaminophenThe serum concentration of Bosutinib can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe serum concentration of Bosutinib can be increased when it is combined with Acetazolamide.Approved, Vet Approved
Acetyl sulfisoxazoleThe serum concentration of Bosutinib can be increased when it is combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Bosutinib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Bosutinib.Experimental
AfatinibThe serum concentration of Bosutinib can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Bosutinib can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe serum concentration of Bosutinib can be increased when it is combined with Aldesleukin.Approved
AlectinibThe serum concentration of Bosutinib can be increased when it is combined with Alectinib.Approved, Investigational
AlfentanilThe serum concentration of Bosutinib can be increased when it is combined with Alfentanil.Approved, Illicit
AlmasilateThe serum concentration of Bosutinib can be decreased when it is combined with Almasilate.Approved, Experimental
AloglutamolThe serum concentration of Bosutinib can be decreased when it is combined with Aloglutamol.Approved
AlprazolamThe serum concentration of Bosutinib can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AluminiumThe serum concentration of Bosutinib can be decreased when it is combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe serum concentration of Bosutinib can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Bosutinib can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Bosutinib can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
AmantadineThe serum concentration of Bosutinib can be increased when it is combined with Amantadine.Approved
AmbroxolThe serum concentration of Bosutinib can be increased when it is combined with Ambroxol.Approved, Investigational
Aminohippuric acidThe serum concentration of Bosutinib can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AmiodaroneThe serum concentration of Bosutinib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Bosutinib can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Bosutinib can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Bosutinib can be increased when it is combined with Amprenavir.Approved, Investigational
AmsacrineThe serum concentration of Bosutinib can be increased when it is combined with Amsacrine.Approved, Investigational
AnastrozoleThe serum concentration of Bosutinib can be increased when it is combined with Anastrozole.Approved, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Bosutinib.Approved, Investigational, Withdrawn
AntipyrineThe serum concentration of Bosutinib can be increased when it is combined with Antipyrine.Approved, Investigational
ApalutamideThe serum concentration of Bosutinib can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Bosutinib can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Bosutinib can be increased when it is combined with Arsenic trioxide.Approved, Investigational
AsenapineThe serum concentration of Bosutinib can be decreased when it is combined with Asenapine.Approved
AstemizoleThe serum concentration of Bosutinib can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Bosutinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Bosutinib can be increased when it is combined with Atenolol.Approved
AtomoxetineThe serum concentration of Bosutinib can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Bosutinib can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Bosutinib can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Bosutinib can be increased when it is combined with Azithromycin.Approved
BenzocaineThe serum concentration of Bosutinib can be increased when it is combined with Benzocaine.Approved, Investigational
BepridilThe serum concentration of Bosutinib can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Bosutinib can be increased when it is combined with Betamethasone.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Bosutinib.Approved, Investigational
BicalutamideThe serum concentration of Bosutinib can be increased when it is combined with Bicalutamide.Approved
BifonazoleThe serum concentration of Bosutinib can be increased when it is combined with Bifonazole.Approved, Investigational
BiperidenThe serum concentration of Bosutinib can be increased when it is combined with Biperiden.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Bosutinib can be decreased when it is combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe serum concentration of Bosutinib can be decreased when it is combined with Bismuth subnitrate.Approved
BoceprevirThe serum concentration of Bosutinib can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Bosutinib can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosutinib can be decreased when it is combined with Bosentan.Approved, Investigational
Brentuximab vedotinThe serum concentration of Bosutinib can be increased when it is combined with Brentuximab vedotin.Approved, Investigational
BromocriptineThe serum concentration of Bosutinib can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Bosutinib can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Bosutinib can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Bosutinib can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe serum concentration of Bosutinib can be increased when it is combined with Cabergoline.Approved
CaffeineThe serum concentration of Bosutinib can be increased when it is combined with Caffeine.Approved
Calcium CarbonateThe serum concentration of Bosutinib can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe serum concentration of Bosutinib can be decreased when it is combined with Calcium silicate.Experimental
CanagliflozinThe serum concentration of Bosutinib can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Bosutinib can be increased when it is combined with Candesartan.Experimental
Candesartan cilexetilThe serum concentration of Bosutinib can be increased when it is combined with Candesartan cilexetil.Approved
CapsaicinThe serum concentration of Bosutinib can be increased when it is combined with Capsaicin.Approved
CaptoprilThe serum concentration of Bosutinib can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Bosutinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Bosutinib can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Bosutinib can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Bosutinib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Bosutinib can be increased when it is combined with Cerivastatin.Approved, Withdrawn
ChloramphenicolThe serum concentration of Bosutinib can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Bosutinib can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorpromazineThe serum concentration of Bosutinib can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe serum concentration of Bosutinib can be increased when it is combined with Chlorpropamide.Approved, Investigational
ChlorprothixeneThe serum concentration of Bosutinib can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe serum concentration of Bosutinib can be increased when it is combined with Chlorzoxazone.Approved
CholesterolThe serum concentration of Bosutinib can be increased when it is combined with Cholesterol.Approved, Investigational
CilazaprilThe serum concentration of Bosutinib can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Bosutinib can be increased when it is combined with Cilostazol.Approved, Investigational
CimetidineThe serum concentration of Bosutinib can be increased when it is combined with Cimetidine.Approved, Investigational
Cimicifuga racemosaThe serum concentration of Bosutinib can be increased when it is combined with Cimicifuga racemosa.Approved, Experimental
CiprofloxacinThe serum concentration of Bosutinib can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Bosutinib can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Bosutinib can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Bosutinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Bosutinib can be increased when it is combined with Clemastine.Approved, Investigational
ClindamycinThe serum concentration of Bosutinib can be increased when it is combined with Clindamycin.Approved, Vet Approved
ClofazimineThe serum concentration of Bosutinib can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Bosutinib can be increased when it is combined with Clomifene.Approved, Investigational
ClomipramineThe serum concentration of Bosutinib can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
ClotiazepamThe serum concentration of Bosutinib can be increased when it is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe serum concentration of Bosutinib can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Bosutinib can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Bosutinib can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Bosutinib can be increased when it is combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Bosutinib can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Bosutinib can be increased when it is combined with Colforsin.Experimental, Investigational
ConivaptanThe serum concentration of Bosutinib can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe serum concentration of Bosutinib can be increased when it is combined with Cortisone acetate.Approved, Investigational
CrizotinibThe serum concentration of Bosutinib can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Bosutinib can be increased when it is combined with Curcumin.Approved, Investigational
CyclophosphamideThe serum concentration of Bosutinib can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Bosutinib can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Bosutinib.Experimental
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bosutinib.Approved
DabrafenibThe serum concentration of Bosutinib can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Bosutinib can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Bosutinib can be increased when it is combined with Dactinomycin.Approved, Investigational
DalfopristinThe serum concentration of Bosutinib can be increased when it is combined with Dalfopristin.Approved
DanazolThe serum concentration of Bosutinib can be increased when it is combined with Danazol.Approved
DarunavirThe serum concentration of Bosutinib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Bosutinib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Bosutinib can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Bosutinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Bosutinib can be increased when it is combined with Delavirdine.Approved
DesipramineThe serum concentration of Bosutinib can be increased when it is combined with Desipramine.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Bosutinib.Approved
DesloratadineThe serum concentration of Bosutinib can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Bosutinib can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexlansoprazoleThe serum concentration of Bosutinib can be decreased when it is combined with Dexlansoprazole.Approved, Investigational
DexrabeprazoleThe serum concentration of Bosutinib can be decreased when it is combined with Dexrabeprazole.Experimental
DextromethorphanThe serum concentration of Bosutinib can be increased when it is combined with Dextromethorphan.Approved
DextropropoxypheneThe serum concentration of Bosutinib can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiacereinThe serum concentration of Bosutinib can be increased when it is combined with Diacerein.Approved, Investigational
DiazepamThe serum concentration of Bosutinib can be increased when it is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe serum concentration of Bosutinib can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Bosutinib can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DigitoxinDigitoxin may decrease the cardiotoxic activities of Bosutinib.Approved, Investigational
DigoxinThe serum concentration of Bosutinib can be increased when it is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bosutinib.Approved
DihydroergotamineThe serum concentration of Bosutinib can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe serum concentration of Bosutinib can be increased when it is combined with Diltiazem.Approved, Investigational
Dimethyl sulfoxideThe serum concentration of Bosutinib can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DipyridamoleThe serum concentration of Bosutinib can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Bosutinib can be increased when it is combined with Docetaxel.Approved, Investigational
DoxazosinThe serum concentration of Bosutinib can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Bosutinib can be increased when it is combined with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Bosutinib can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Bosutinib can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Bosutinib can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Bosutinib can be increased when it is combined with Dronedarone.Approved
EconazoleThe serum concentration of Bosutinib can be increased when it is combined with Econazole.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Bosutinib.Approved
EfavirenzThe serum concentration of Bosutinib can be increased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe serum concentration of Bosutinib can be increased when it is combined with Efonidipine.Approved, Investigational
ElbasvirThe serum concentration of Bosutinib can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Bosutinib can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Bosutinib can be increased when it is combined with Enasidenib.Approved, Investigational
EnzalutamideThe serum concentration of Bosutinib can be increased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Bosutinib can be decreased when it is combined with Epinastine.Approved, Investigational
EpinephrineThe serum concentration of Bosutinib can be increased when it is combined with Epinephrine.Approved, Vet Approved
ErgonovineThe serum concentration of Bosutinib can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Bosutinib can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Bosutinib can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EsomeprazoleThe serum concentration of Bosutinib can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstramustineThe serum concentration of Bosutinib can be increased when it is combined with Estramustine.Approved, Investigational
EthanolThe serum concentration of Bosutinib can be increased when it is combined with Ethanol.Approved
EtoposideThe serum concentration of Bosutinib can be increased when it is combined with Etoposide.Approved
EtoricoxibThe serum concentration of Bosutinib can be increased when it is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Bosutinib can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Bosutinib.Approved
EzetimibeThe serum concentration of Bosutinib can be increased when it is combined with Ezetimibe.Approved
FamotidineThe serum concentration of Bosutinib can be decreased when it is combined with Famotidine.Approved
FelodipineThe serum concentration of Bosutinib can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Bosutinib can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Bosutinib can be increased when it is combined with Fexofenadine.Approved, Investigational
FidaxomicinThe serum concentration of Bosutinib can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe serum concentration of Bosutinib can be increased when it is combined with Fluconazole.Approved, Investigational
FluoxetineThe serum concentration of Bosutinib can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Bosutinib can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Bosutinib can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Bosutinib can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
Fluticasone propionateThe serum concentration of Bosutinib can be increased when it is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Bosutinib can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Bosutinib can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Bosutinib can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Bosutinib can be increased when it is combined with Fosaprepitant.Approved
FosnetupitantThe serum concentration of Bosutinib can be increased when it is combined with Fosnetupitant.Approved
FosphenytoinThe serum concentration of Bosutinib can be decreased when it is combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Bosutinib can be increased when it is combined with Fusidic Acid.Approved, Investigational
GefitinibThe serum concentration of Bosutinib can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe serum concentration of Bosutinib can be increased when it is combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Bosutinib can be increased when it is combined with Genistein.Investigational
GestodeneThe serum concentration of Bosutinib can be increased when it is combined with Gestodene.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Bosutinib.Experimental
GlecaprevirThe serum concentration of Bosutinib can be increased when it is combined with Glecaprevir.Approved, Investigational
GlyburideThe serum concentration of Bosutinib can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Bosutinib can be increased when it is combined with Glycerin.Approved, Investigational
Glycerol PhenylbutyrateThe serum concentration of Bosutinib can be increased when it is combined with Glycerol Phenylbutyrate.Approved
Gramicidin DThe serum concentration of Bosutinib can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Bosutinib can be increased when it is combined with Grepafloxacin.Approved, Investigational, Withdrawn
HaloperidolThe serum concentration of Bosutinib can be increased when it is combined with Haloperidol.Approved
HistamineThe serum concentration of Bosutinib can be increased when it is combined with Histamine.Approved, Investigational
HydralazineThe serum concentration of Bosutinib can be increased when it is combined with Hydralazine.Approved
HydrocortisoneThe serum concentration of Bosutinib can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydrotalciteThe serum concentration of Bosutinib can be decreased when it is combined with Hydrotalcite.Approved, Experimental, Investigational
IdelalisibThe serum concentration of Bosutinib can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Bosutinib can be increased when it is combined with Ifosfamide.Approved
IloperidoneThe serum concentration of Bosutinib can be increased when it is combined with Iloperidone.Approved
ImatinibThe serum concentration of Bosutinib can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Bosutinib can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Bosutinib can be increased when it is combined with Indinavir.Approved
IndisulamThe serum concentration of Bosutinib can be increased when it is combined with Indisulam.Investigational
IndomethacinThe serum concentration of Bosutinib can be increased when it is combined with Indomethacin.Approved, Investigational
IrbesartanThe serum concentration of Bosutinib can be increased when it is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Bosutinib can be increased when it is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe serum concentration of Bosutinib can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Bosutinib can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe serum concentration of Bosutinib can be increased when it is combined with Isoniazid.Approved, Investigational
IsradipineThe serum concentration of Bosutinib can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Bosutinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Bosutinib can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Bosutinib can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
JosamycinThe serum concentration of Bosutinib can be increased when it is combined with Josamycin.Approved, Investigational
KetamineThe serum concentration of Bosutinib can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Bosutinib can be increased when it is combined with Ketazolam.Approved
KetoconazoleThe serum concentration of Bosutinib can be increased when it is combined with Ketoconazole.Approved, Investigational
LafutidineThe serum concentration of Bosutinib can be decreased when it is combined with Lafutidine.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Bosutinib.Experimental
LansoprazoleThe serum concentration of Bosutinib can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Bosutinib can be increased when it is combined with Lapatinib.Approved, Investigational
LavoltidineThe serum concentration of Bosutinib can be decreased when it is combined with Lavoltidine.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Bosutinib.Approved
LercanidipineThe serum concentration of Bosutinib can be increased when it is combined with Lercanidipine.Approved, Investigational
LetermovirThe serum concentration of Bosutinib can be increased when it is combined with Letermovir.Approved, Investigational
LevofloxacinThe serum concentration of Bosutinib can be increased when it is combined with Levofloxacin.Approved, Investigational
LevosalbutamolThe serum concentration of Bosutinib can be increased when it is combined with Levosalbutamol.Approved, Investigational
LidocaineThe serum concentration of Bosutinib can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Bosutinib can be increased when it is combined with Linagliptin.Approved
LipegfilgrastimBosutinib may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LomitapideThe serum concentration of Bosutinib can be increased when it is combined with Lomitapide.Approved, Investigational
LomustineThe serum concentration of Bosutinib can be increased when it is combined with Lomustine.Approved, Investigational
LoperamideThe serum concentration of Bosutinib can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Bosutinib can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Bosutinib can be increased when it is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Bosutinib can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Bosutinib can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Bosutinib can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Bosutinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Bosutinib can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe serum concentration of Bosutinib can be increased when it is combined with Lurasidone.Approved, Investigational
MagaldrateThe serum concentration of Bosutinib can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
Magnesium hydroxideThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium silicate.Approved
Magnesium TrisilicateThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium Trisilicate.Approved
ManidipineThe serum concentration of Bosutinib can be increased when it is combined with Manidipine.Approved, Investigational
MaprotilineThe serum concentration of Bosutinib can be increased when it is combined with Maprotiline.Approved, Investigational
MebendazoleThe serum concentration of Bosutinib can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Bosutinib can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Bosutinib can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MeprobamateThe serum concentration of Bosutinib can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineThe serum concentration of Bosutinib can be increased when it is combined with Mequitazine.Approved
MetamizoleThe risk or severity of myelosuppression can be increased when Metamizole is combined with Bosutinib.Approved, Investigational, Withdrawn
MethadoneThe serum concentration of Bosutinib can be increased when it is combined with Methadone.Approved
MethanthelineThe serum concentration of Bosutinib can be decreased when it is combined with Methantheline.Approved, Investigational
MethazolamideThe serum concentration of Bosutinib can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Bosutinib can be increased when it is combined with Methimazole.Approved
MethylergometrineThe serum concentration of Bosutinib can be increased when it is combined with Methylergometrine.Approved
MethylprednisoloneThe serum concentration of Bosutinib can be increased when it is combined with Methylprednisolone.Approved, Vet Approved
MetiamideThe serum concentration of Bosutinib can be decreased when it is combined with Metiamide.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Bosutinib.Experimental
MetoprololThe serum concentration of Bosutinib can be increased when it is combined with Metoprolol.Approved, Investigational
MetronidazoleThe serum concentration of Bosutinib can be increased when it is combined with Metronidazole.Approved
MetyraponeThe serum concentration of Bosutinib can be increased when it is combined with Metyrapone.Approved, Investigational
MibefradilThe serum concentration of Bosutinib can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Bosutinib can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Bosutinib can be increased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe serum concentration of Bosutinib can be increased when it is combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Bosutinib can be increased when it is combined with Mifepristone.Approved, Investigational
MirtazapineThe serum concentration of Bosutinib can be increased when it is combined with Mirtazapine.Approved
MitomycinThe serum concentration of Bosutinib can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Bosutinib can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Bosutinib can be increased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Bosutinib can be increased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Bosutinib can be increased when it is combined with Morphine.Approved, Investigational
NabiloneThe serum concentration of Bosutinib can be increased when it is combined with Nabilone.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Bosutinib.Approved
NaltrexoneThe serum concentration of Bosutinib can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Bosutinib can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of Bosutinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Bosutinib can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Bosutinib can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Bosutinib can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Bosutinib can be increased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Bosutinib can be increased when it is combined with Nicardipine.Approved, Investigational
NicotinamideThe serum concentration of Bosutinib can be increased when it is combined with Nicotinamide.Approved, Investigational
NifedipineThe serum concentration of Bosutinib can be increased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Bosutinib can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineThe serum concentration of Bosutinib can be increased when it is combined with Nilvadipine.Approved, Investigational
NiperotidineThe serum concentration of Bosutinib can be decreased when it is combined with Niperotidine.Experimental, Investigational
NisoldipineThe serum concentration of Bosutinib can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Bosutinib can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Bosutinib can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe serum concentration of Bosutinib can be increased when it is combined with Nitric Oxide.Approved
NizatidineThe serum concentration of Bosutinib can be decreased when it is combined with Nizatidine.Approved
NorfloxacinThe serum concentration of Bosutinib can be increased when it is combined with Norfloxacin.Approved
NoscapineThe serum concentration of Bosutinib can be increased when it is combined with Noscapine.Investigational
OlanzapineThe serum concentration of Bosutinib can be increased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Bosutinib can be increased when it is combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Bosutinib.Experimental, Investigational
OmeprazoleThe serum concentration of Bosutinib can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Bosutinib can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Bosutinib.Approved
OxetacaineThe serum concentration of Bosutinib can be increased when it is combined with Oxetacaine.Approved, Investigational
OxybutyninThe serum concentration of Bosutinib can be increased when it is combined with Oxybutynin.Approved, Investigational
OxymetholoneThe serum concentration of Bosutinib can be increased when it is combined with Oxymetholone.Approved, Illicit
P-NitrophenolThe serum concentration of Bosutinib can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Bosutinib can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Bosutinib can be increased when it is combined with Palbociclib.Approved, Investigational
Palmitic AcidThe serum concentration of Bosutinib can be increased when it is combined with Palmitic Acid.Approved, Experimental
PantoprazoleThe serum concentration of Bosutinib can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe serum concentration of Bosutinib can be increased when it is combined with Paramethasone.Approved
ParoxetineThe serum concentration of Bosutinib can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Bosutinib.Approved
PentobarbitalThe serum concentration of Bosutinib can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
Peppermint oilThe serum concentration of Bosutinib can be increased when it is combined with Peppermint oil.Approved, Investigational
PergolideThe serum concentration of Bosutinib can be increased when it is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Bosutinib can be increased when it is combined with Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Bosutinib.Experimental
PhenelzineThe serum concentration of Bosutinib can be increased when it is combined with Phenelzine.Approved
PhenobarbitalThe serum concentration of Bosutinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenytoinThe serum concentration of Bosutinib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Bosutinib can be increased when it is combined with Pibrentasvir.Approved, Investigational
PilocarpineThe serum concentration of Bosutinib can be increased when it is combined with Pilocarpine.Approved, Investigational
PimozideThe serum concentration of Bosutinib can be increased when it is combined with Pimozide.Approved
PiperaquineThe serum concentration of Bosutinib can be increased when it is combined with Piperaquine.Approved, Investigational
PitolisantThe serum concentration of Bosutinib can be decreased when it is combined with Pitolisant.Approved, Investigational
PonatinibThe serum concentration of Bosutinib can be increased when it is combined with Ponatinib.Approved, Investigational
PosaconazoleThe serum concentration of Bosutinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Bosutinib can be increased when it is combined with Prasterone.Approved, Investigational, Nutraceutical
PravastatinThe serum concentration of Bosutinib can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Bosutinib can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Bosutinib can be increased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Bosutinib can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Bosutinib can be increased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Bosutinib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Bosutinib can be increased when it is combined with Probenecid.Approved, Investigational
ProgesteroneThe serum concentration of Bosutinib can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Bosutinib can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Bosutinib can be increased when it is combined with Propafenone.Approved
PropofolThe serum concentration of Bosutinib can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Bosutinib can be increased when it is combined with Propranolol.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Bosutinib.Experimental
ProtriptylineThe serum concentration of Bosutinib can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Bosutinib.Approved
QuercetinThe serum concentration of Bosutinib can be increased when it is combined with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of Bosutinib can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidineThe serum concentration of Bosutinib can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Bosutinib can be increased when it is combined with Quinine.Approved
QuinupristinThe serum concentration of Bosutinib can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe serum concentration of Bosutinib can be increased when it is combined with Rabeprazole.Approved, Investigational
RaloxifeneThe serum concentration of Bosutinib can be increased when it is combined with Raloxifene.Approved, Investigational
RanitidineThe serum concentration of Bosutinib can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Bosutinib can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Bosutinib can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Bosutinib can be increased when it is combined with Regorafenib.Approved
RepaglinideThe serum concentration of Bosutinib can be increased when it is combined with Repaglinide.Approved, Investigational
ReserpineThe serum concentration of Bosutinib can be increased when it is combined with Reserpine.Approved, Investigational
ResveratrolThe serum concentration of Bosutinib can be increased when it is combined with Resveratrol.Approved, Experimental, Investigational
RheinThe serum concentration of Bosutinib can be increased when it is combined with Rhein.Experimental
RifabutinThe serum concentration of Bosutinib can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Bosutinib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bosutinib can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Bosutinib.Approved, Investigational
RilpivirineThe serum concentration of Bosutinib can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Bosutinib can be increased when it is combined with Risperidone.Approved, Investigational
RitonavirThe serum concentration of Bosutinib can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe serum concentration of Bosutinib can be increased when it is combined with Rivastigmine.Approved, Investigational
RolapitantThe serum concentration of Bosutinib can be increased when it is combined with Rolapitant.Approved, Investigational
RolitetracyclineThe serum concentration of Bosutinib can be increased when it is combined with Rolitetracycline.Approved
RosuvastatinThe serum concentration of Bosutinib can be increased when it is combined with Rosuvastatin.Approved
Roxatidine acetateThe serum concentration of Bosutinib can be decreased when it is combined with Roxatidine acetate.Approved, Investigational
RoxithromycinThe serum concentration of Bosutinib can be increased when it is combined with Roxithromycin.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Bosutinib can be increased when it is combined with Rucaparib.Approved, Investigational
RutinThe serum concentration of Bosutinib can be increased when it is combined with Rutin.Experimental, Investigational
SalbutamolThe serum concentration of Bosutinib can be increased when it is combined with Salbutamol.Approved, Vet Approved
SaquinavirThe serum concentration of Bosutinib can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe serum concentration of Bosutinib can be increased when it is combined with Sarilumab.Approved, Investigational
ScopolamineThe serum concentration of Bosutinib can be increased when it is combined with Scopolamine.Approved, Investigational
SelegilineThe serum concentration of Bosutinib can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SeproxetineThe serum concentration of Bosutinib can be increased when it is combined with Seproxetine.Investigational
SertralineThe serum concentration of Bosutinib can be increased when it is combined with Sertraline.Approved
SildenafilThe serum concentration of Bosutinib can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Bosutinib.Approved
SiltuximabThe serum concentration of Bosutinib can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Bosutinib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Bosutinib can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Bosutinib can be increased when it is combined with Sirolimus.Approved, Investigational
SitaxentanThe serum concentration of Bosutinib can be increased when it is combined with Sitaxentan.Approved, Investigational, Withdrawn
Sodium bicarbonateThe serum concentration of Bosutinib can be decreased when it is combined with Sodium bicarbonate.Approved
SorafenibThe serum concentration of Bosutinib can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Bosutinib can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Bosutinib can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StaurosporineThe serum concentration of Bosutinib can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Bosutinib can be increased when it is combined with Stiripentol.Approved
SulfamethoxazoleThe serum concentration of Bosutinib can be increased when it is combined with Sulfamethoxazole.Approved
SulfanilamideThe serum concentration of Bosutinib can be increased when it is combined with Sulfanilamide.Approved
SulfinpyrazoneThe serum concentration of Bosutinib can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Bosutinib can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Bosutinib can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Bosutinib can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Bosutinib can be increased when it is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe serum concentration of Bosutinib can be increased when it is combined with Tacrolimus.Approved, Investigational
TadalafilThe serum concentration of Bosutinib can be increased when it is combined with Tadalafil.Approved, Investigational
TamoxifenThe serum concentration of Bosutinib can be increased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Bosutinib can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Bosutinib can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Bosutinib can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Bosutinib can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Bosutinib can be increased when it is combined with Temsirolimus.Approved
TeniposideThe serum concentration of Bosutinib can be increased when it is combined with Teniposide.Approved
TerazosinThe serum concentration of Bosutinib can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Bosutinib can be increased when it is combined with Terfenadine.Approved, Withdrawn
TesmilifeneThe serum concentration of Bosutinib can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Bosutinib can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Bosutinib can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Bosutinib can be increased when it is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe serum concentration of Bosutinib can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe serum concentration of Bosutinib can be increased when it is combined with Tetracycline.Approved, Vet Approved
ThiopentalThe serum concentration of Bosutinib can be increased when it is combined with Thiopental.Approved, Vet Approved
TicagrelorThe serum concentration of Bosutinib can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Bosutinib can be increased when it is combined with Ticlopidine.Approved
TioconazoleThe serum concentration of Bosutinib can be increased when it is combined with Tioconazole.Approved
TipranavirThe serum concentration of Bosutinib can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Bosutinib can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe serum concentration of Bosutinib can be increased when it is combined with Tofisopam.Approved
TolvaptanThe serum concentration of Bosutinib can be increased when it is combined with Tolvaptan.Approved
TopiroxostatThe serum concentration of Bosutinib can be increased when it is combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Bosutinib.Approved, Investigational
TramadolThe serum concentration of Bosutinib can be increased when it is combined with Tramadol.Approved, Investigational
TranylcypromineThe serum concentration of Bosutinib can be increased when it is combined with Tranylcypromine.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Bosutinib.Approved, Investigational
TrifluoperazineThe serum concentration of Bosutinib can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Bosutinib can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Bosutinib can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Bosutinib can be increased when it is combined with Trimipramine.Approved
TroglitazoneThe serum concentration of Bosutinib can be increased when it is combined with Troglitazone.Investigational, Withdrawn
TroleandomycinThe serum concentration of Bosutinib can be increased when it is combined with Troleandomycin.Approved
TromethamineThe serum concentration of Bosutinib can be decreased when it is combined with Tromethamine.Approved
Valproic AcidThe serum concentration of Bosutinib can be increased when it is combined with Valproic Acid.Approved, Investigational
VelpatasvirThe serum concentration of Bosutinib can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Bosutinib can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Bosutinib can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Bosutinib can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Bosutinib can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Bosutinib can be increased when it is combined with Vincristine.Approved, Investigational
VincristineThe excretion of Vincristine can be decreased when combined with Bosutinib.Approved, Investigational
VinorelbineThe serum concentration of Bosutinib can be increased when it is combined with Vinorelbine.Approved, Investigational
VoacamineThe serum concentration of Bosutinib can be increased when it is combined with Voacamine.Approved, Investigational
VoriconazoleThe serum concentration of Bosutinib can be increased when it is combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Bosutinib can be increased when it is combined with Voxilaprevir.Approved, Investigational
ZafirlukastThe serum concentration of Bosutinib can be increased when it is combined with Zafirlukast.Approved, Investigational
ZimelidineThe serum concentration of Bosutinib can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Bosutinib can be increased when it is combined with Ziprasidone.Approved
ZucapsaicinThe serum concentration of Bosutinib can be increased when it is combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • When given with a high fat meal, the Cmax and AUC of bosutinib increased 1.8- and 1.7-fold, respectively.

References

General References
  1. Amsberg GK, Schafhausen P: Bosutinib in the management of chronic myelogenous leukemia. Biologics. 2013;7:115-22. doi: 10.2147/BTT.S30182. Epub 2013 May 6. [PubMed:23674887]
  2. Keller-V Amsberg G, Brummendorf TH: Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2012 Sep;12(9):1121-7. doi: 10.1586/era.12.84. [PubMed:23098112]
  3. Link [Link]
External Links
Human Metabolome Database
HMDB0240205
KEGG Drug
D03252
PubChem Compound
5328940
PubChem Substance
175427079
ChemSpider
4486102
BindingDB
4552
ChEBI
39112
ChEMBL
CHEMBL288441
HET
DB8
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Bosutinib
ATC Codes
L01XE14 — Bosutinib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
3soa / 3ue4 / 4mxo / 4mxx / 4mxy / 4mxz / 4otw / 4qmn / 5ajq / 5i9x
show 2 more
FDA label
Download (326 KB)
MSDS
Download (97.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableCancer, Breast / Leukemia,Myeloid, Chronic1
1CompletedNot AvailableCancer, Breast / Leukemias / Tumors1
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers8
1CompletedTreatmentNeoplasms1
1CompletedTreatmentPhiladelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)1
1CompletedTreatmentRenal Disease, End-Stage / Renal Insufficiency, Acute / Renal Insufficiency,Chronic1
1CompletedTreatmentTumors1
1Enrolling by InvitationTreatmentDementias / Mild Cognitive Impairment (MCI)1
1RecruitingTreatmentAdvanced thymic carcinoma / Bladder Cancers / Cancer of the Ovary / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Peritoneal Neoplasm / Mesothelioma / Thymus Cancer / Uterine Cervical Cancer1
1TerminatedTreatmentMalignant Neoplasm of Pancreas1
1, 2CompletedTreatmentChronic Myeloid Leukemia (CML)1
1, 2RecruitingTreatmentLeukemias2
1, 2TerminatedTreatmentAdvanced Breast Cancer (Parts 1 and 2) / Advanced Cholangiocarcinoma (Part 1) / Advanced Colorectal Cancer (Part 1) / Advanced Glioblastoma Multiforme (Part 1) / Advanced Pancreatic Cancer (Part 1)1
2Active Not RecruitingTreatmentChronic Myeloblastic Leukaemia1
2Active Not RecruitingTreatmentChronic Myelogenous Leukemia (CML)1
2CompletedTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
2CompletedTreatmentChronic Myelogenous Leukemia (CML)1
2CompletedTreatmentGlioblastomas1
2CompletedTreatmentNeoplasms Metastasis / Neoplasms, Breast1
2RecruitingTreatmentAdvanced Solid Tumors / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)2
2RecruitingTreatmentBCR-ABL Positive / Chronic / Leukemias / Myelogenous1
2RecruitingTreatmentChronic Myelogenous Leukaemia1
2RecruitingTreatmentChronic Myelogenous Leukemia (CML)1
2RecruitingTreatmentChronic Myeloid Leukemia (CML)1
2TerminatedTreatmentAdvanced Breast Cancer1
2TerminatedTreatmentCancer, Breast1
3Active Not RecruitingTreatmentLeukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive1
3CompletedTreatmentChronic Myeloid Leukemia (CML)1
3RecruitingTreatmentChronic Myelogenous Leukemia (CML)1
4Active Not RecruitingTreatmentPreviously Treated PH + CML1
Not AvailableActive Not RecruitingNot AvailableChronic Myelogenous Leukemia (CML)1
Not AvailableActive Not RecruitingNot AvailableChronic Myeloid Leukemia (CML)1
Not AvailableCompletedNot AvailableChronic Myeloid Leukemia (CML)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral500 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral100 mg
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral500 mg
Tablet, film coatedOral500 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6002008No1998-03-272018-03-27Us
US7417148No2006-01-232026-01-23Us
USRE42376No1999-09-242019-09-24Us
US7767678No2006-11-232026-11-23Us
US7919625No2005-12-112025-12-11Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0095 mg/mLALOGPS
logP4.87ALOGPS
logP4.09ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)15.48ChemAxon
pKa (Strongest Basic)8.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area82.88 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity142.12 m3·mol-1ChemAxon
Polarizability56.14 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9823
Blood Brain Barrier+0.9272
Caco-2 permeable+0.6542
P-glycoprotein substrateSubstrate0.7601
P-glycoprotein inhibitor IInhibitor0.8409
P-glycoprotein inhibitor IIInhibitor0.9108
Renal organic cation transporterInhibitor0.5663
CYP450 2C9 substrateNon-substrate0.854
CYP450 2D6 substrateNon-substrate0.6953
CYP450 3A4 substrateSubstrate0.6987
CYP450 1A2 substrateInhibitor0.5606
CYP450 2C9 inhibitorNon-inhibitor0.7372
CYP450 2D6 inhibitorNon-inhibitor0.5136
CYP450 2C19 inhibitorNon-inhibitor0.5725
CYP450 3A4 inhibitorInhibitor0.5
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7021
Ames testAMES toxic0.5922
CarcinogenicityNon-carcinogens0.8869
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4201 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6147
hERG inhibition (predictor II)Inhibitor0.7754
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0092000000-68183c460c3cf8e08c01
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001l-1900080000-86f44693fc4098040447

Taxonomy

Description
This compound belongs to the class of organic compounds known as 4-aminoquinolines. These are organic compounds containing an amino group attached to the 4-position of a quinoline ring system.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Aminoquinolines and derivatives
Direct Parent
4-aminoquinolines
Alternative Parents
Aminophenyl ethers / Methoxyanilines / Phenoxy compounds / Anisoles / Dichlorobenzenes / Methoxybenzenes / Alkyl aryl ethers / Aminopyridines and derivatives / N-methylpiperazines / Aryl chlorides
show 8 more
Substituents
4-aminoquinoline / Methoxyaniline / Aminophenyl ether / Anisole / 1,3-dichlorobenzene / Phenol ether / Aniline or substituted anilines / Methoxybenzene / Phenoxy compound / Alkyl aryl ether
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, aromatic ether, nitrile, dichlorobenzene, aminoquinoline, N-methylpiperazine (CHEBI:39112)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Rho guanyl-nucleotide exchange factor activity
Specific Function
GTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase activity.
Gene Name
BCR
Uniprot ID
P11274
Uniprot Name
Breakpoint cluster region protein
Molecular Weight
142818.07 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Syntaxin binding
Specific Function
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility a...
Gene Name
ABL1
Uniprot ID
P00519
Uniprot Name
Tyrosine-protein kinase ABL1
Molecular Weight
122871.435 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Receptor signaling protein tyrosine kinase activity
Specific Function
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, respons...
Gene Name
LYN
Uniprot ID
P07948
Uniprot Name
Tyrosine-protein kinase Lyn
Molecular Weight
58573.595 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Receptor binding
Specific Function
Non-receptor tyrosine-protein kinase found in hematopoietic cells that transmits signals from cell surface receptors and plays an important role in the regulation of innate immune responses, includ...
Gene Name
HCK
Uniprot ID
P08631
Uniprot Name
Tyrosine-protein kinase HCK
Molecular Weight
59599.355 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sh3/sh2 adaptor activity
Specific Function
Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion recept...
Gene Name
SRC
Uniprot ID
P12931
Uniprot Name
Proto-oncogene tyrosine-protein kinase Src
Molecular Weight
59834.295 Da
Details
6. Cyclin-dependent kinase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, N...
Gene Name
CDK2
Uniprot ID
P24941
Uniprot Name
Cyclin-dependent kinase 2
Molecular Weight
33929.215 Da
References
  1. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Muller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G: Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27. [PubMed:19039322]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Receptor signaling protein tyrosine phosphatase activity
Specific Function
Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones t...
Gene Name
MAP2K1
Uniprot ID
Q02750
Uniprot Name
Dual specificity mitogen-activated protein kinase kinase 1
Molecular Weight
43438.65 Da
References
  1. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Muller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G: Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27. [PubMed:19039322]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).
Gene Name
MAP2K2
Uniprot ID
P36507
Uniprot Name
Dual specificity mitogen-activated protein kinase kinase 2
Molecular Weight
44423.735 Da
References
  1. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Muller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G: Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27. [PubMed:19039322]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein serine/threonine kinase activity
Specific Function
Component of a protein kinase signal transduction cascade. Regulates the JNK and ERK5 pathways by phosphorylating and activating MAP2K5 and MAP2K7 (By similarity). Plays a role in caveolae kiss-and...
Gene Name
MAP3K2
Uniprot ID
Q9Y2U5
Uniprot Name
Mitogen-activated protein kinase kinase kinase 2
Molecular Weight
69740.21 Da
References
  1. Ahmad S, Hughes MA, Johnson GL, Scott JE: Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors. J Biomol Screen. 2013 Apr;18(4):388-99. doi: 10.1177/1087057112466430. Epub 2012 Nov 7. [PubMed:23134735]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein homodimerization activity
Specific Function
Calcium/calmodulin-dependent protein kinase that functions autonomously after Ca(2+)/calmodulin-binding and autophosphorylation, and is involved in sarcoplsamic reticulum Ca(2+) transport in skelet...
Gene Name
CAMK2G
Uniprot ID
Q13555
Uniprot Name
Calcium/calmodulin-dependent protein kinase type II subunit gamma
Molecular Weight
62608.655 Da
References
  1. Amsberg GK, Koschmieder S: Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia. Onco Targets Ther. 2013;6:99-106. doi: 10.2147/OTT.S19901. Epub 2013 Mar 4. [PubMed:23493838]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da

Drug created on March 19, 2008 10:41 / Updated on June 24, 2018 20:22